Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice
暂无分享,去创建一个
L. Glimcher | S. Ostrand-Rosenberg | S. Baskar | N. Nabavi | R. Jones | R. Jones | Sivasubramanian | Baskar | Nasr in | Nabavi | T. Jones
[1] Lieping Chen,et al. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. , 1994, Journal of immunology.
[2] S. Ostrand-Rosenberg,et al. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. , 1994, Cellular immunology.
[3] M. Sitkovsky,et al. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells. , 1994, Journal of immunology.
[4] J. Johnston,et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.
[5] Simon C Watkins,et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. , 1994, Cancer research.
[6] S. Ostrand-Rosenberg,et al. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection. , 1993, Journal of immunology.
[7] H. Ananthaswamy,et al. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. , 1993, Journal of immunology.
[8] G. Freeman,et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Allison,et al. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help , 1993, The Journal of experimental medicine.
[10] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[11] F. Miller,et al. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. , 1993, Journal of the National Cancer Institute.
[12] E. Gilboa,et al. Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells [published erratum appears in J Exp Med 1993 Jun 1;177(6):following 1831] , 1993, The Journal of experimental medicine.
[13] L. Lanier,et al. Requirements for CD28-dependent T cell-mediated cytotoxicity. , 1993, Journal of immunology.
[14] J. Allison,et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.
[15] P. Linsley,et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.
[16] G. Freeman,et al. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. , 1992, Journal of immunology.
[17] G. Freeman,et al. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression , 1992, Nature.
[18] C. Janeway,et al. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. Pardoll. New strategies for active immunotherapy with genetically engineered tumor cells. , 1992, Current opinion in immunology.
[20] D. Pardoll,et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.
[21] S. Ostrand-Rosenberg,et al. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. , 1991, Journal of immunology.
[22] Eric O Long,et al. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells , 1990, The Journal of experimental medicine.
[23] S. Ostrand-Rosenberg,et al. Rejection of mouse sarcoma cells after transfection of MHC class II genes. , 1990, Journal of immunology.
[24] R. Klausner,et al. Class II MHC molecules can use the endogenous pathway of antigen presentation , 1990, Nature.
[25] Eric O Long,et al. HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells , 1989, Journal of virology.
[26] R. Schwartz,et al. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.
[27] P. Marrack,et al. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. , 1983, Journal of immunology.
[28] A. Glasebrook,et al. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. , 1980, Journal of immunology.
[29] L. Herzenberg,et al. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. , 1978, Current topics in microbiology and immunology.